Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology
13 juin 2023 09h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., June 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that it has entered into a collaboration agreement with a NY-based...
Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
08 juin 2023 08h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., June 08, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced it has entered into securities purchase agreements with...
Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects
07 juin 2023 09h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., June 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that several operational improvement initiatives which commenced at...
Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
22 mai 2023 11h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a...
Precipio Shares Growth Catalysts For HemeScreen
17 mai 2023 16h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 17, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be discussing on today’s shareholders call several growth catalysts that...
Precipio Announces Q1-2023 Shareholder Update Call
15 mai 2023 16h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2023 corporate update call on May 17th at 5:00 PM ET....
Precipio Adds Substantial Pathology Customer to its Diagnostic Services Division
04 mai 2023 13h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new pathology services customer to utilize...
Precipio Signs Another HemeScreen™ Customer
04 mai 2023 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 04, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces another agreement with a new customer to bring HemeScreen™ technology...
Precipio Granted 180-day Extension From NASDAQ To Regain Compliance
27 avr. 2023 17h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., April 27, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces notification by the NASDAQ Stock Market that the Company has been...
Precipio Unaudited Q1-2023 Product Revenues Exceed The Two Prior Quarters (Q3+Q4 of 2022) Combined
19 avr. 2023 11h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., April 19, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q1-2023 product revenues have surpassed product revenues...